ProQR Therapeutics N.V. (PRQR) Income Statement
PRQR 2025 at a glance
Fiscal year ended December 31, 2025 · eurosPRQR revenue and net income
Where PRQR's revenue goes
2025Each bar shows an amount and its share of revenue. PRQR kept −265.2% of revenue as net income.
PRQR profit margins
PRQR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −19.2% | +62.0% | +71.5% | +5.0% |
| Gross profit | −32.9% | +52.2% | +65.3% | +3.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PRQR income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €15.3M | €18.9M | €6.5M | €3.6M | €1.3M | €1.0M | €1.9M | €4.9M | €0 | €2.3M |
| Cost of revenue | €2.6M | €0 | €133,524 | €2.5M | €0 | €2.2M | €116.8M | €983,511 | €1.0M | €1.3M |
| Gross profit | €12.7M | €18.9M | €6.5M | €3.6M | €1.3M | €1.0M | −€114.9M | €4.0M | −€2.5M | €1.0M |
| Research & development | €40.7M | €36.4M | €25.1M | €50.9M | €42.2M | €38.1M | €46.5M | €29.5M | €31.2M | €31.9M |
| Sales, general & admin | €15.1M | €13.7M | €16.2M | €18.7M | €17.4M | €13.7M | €12.9M | €12.5M | €10.8M | €9.5M |
| Total operating expenses | €54.8M | €49.4M | €38.4M | €68.8M | €58.5M | €43.4M | €59.4M | €42.1M | €42.0M | €41.4M |
| Operating income | −€42.2M | −€30.5M | −€31.9M | −€65.2M | −€57.2M | −€42.4M | −€57.4M | −€36.3M | −€40.5M | −€39.6M |
| Interest income | €2.3M | €3.3M | €2.6M | €106,000 | €5,000 | €313,000 | €763,000 | €189,000 | €90,000 | €270,000 |
| Interest expense | €866,400 | €1.1M | €1.2M | €5.1M | €3.4M | €2.0M | €1.1M | €810,000 | €596,000 | €538,000 |
| Income before taxes | −€40.5M | −€28.0M | −€27.8M | −€64.1M | −€60.7M | −€46.5M | −€56.6M | −€37.1M | −€43.7M | −€39.1M |
| Income taxes | €18,249 | −€197,000 | −€78,000 | €96,000 | €117,000 | €124,000 | €132,000 | €1,000 | €2,000 | −€470,000 |
| Net income | −€40.5M | −€27.8M | −€28.1M | −€64.4M | −€60.7M | −€46.6M | −€56.7M | −€36.9M | −€43.6M | −€39.1M |
| EBITDA | −€36.9M | −€24.1M | −€24.1M | −€56.5M | −€54.9M | −€48.4M | −€170.3M | −€35.3M | €1.1M | −€36.0M |
| Gross margin | 83.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | −5,943.6% | 80.1% | — | 43.8% |
| Operating margin | −275.9% | −161.2% | −489.1% | −1,813.0% | −4,285.4% | −4,117.4% | −2,971.8% | −734.5% | — | −1,734.1% |
| Net margin | −265.2% | −146.9% | −431.7% | −1,792.5% | −4,549.8% | −4,525.3% | −2,935.6% | −746.7% | — | −1,713.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €8.9M | €2.1M | €4.6M | €2.9M | €3.8M | €4.5M | €4.3M | €3.8M | €6.3M | €4.5M | €3.3M | €1.4M |
| Cost of revenue | €718,705 | €705,412 | €672,631 | €0 | €0 | €0 | €0 | €0 | €714,596 | €695,067 | €0 | €0 |
| Gross profit | €8.2M | €1.4M | €4.0M | €2.9M | €3.8M | €4.5M | €4.3M | €3.8M | €6.3M | €4.5M | €3.3M | €1.4M |
| Research & development | €12.9M | €12.0M | €9.8M | €11.1M | €11.4M | €12.3M | €10.6M | €9.4M | €7.0M | €9.3M | €7.7M | €5.4M |
| Sales, general & admin | €4.9M | €3.9M | €3.9M | €3.1M | €4.8M | €3.2M | €3.9M | €3.3M | €3.0M | €3.5M | €4.8M | €3.3M |
| Total operating expenses | €17.2M | €15.2M | €13.0M | €14.2M | €16.1M | €15.3M | €14.4M | €12.6M | €9.9M | €12.5M | €9.6M | €8.8M |
| Operating income | −€9.0M | −€13.9M | −€9.0M | −€11.3M | −€12.2M | −€10.8M | −€10.1M | −€8.7M | −€3.6M | −€8.1M | −€6.3M | −€7.4M |
| Interest expense | — | — | — | — | — | — | — | — | €2,594 | €2,872 | €276,708 | €10,558 |
| Income before taxes | −€8.8M | −€13.6M | −€8.8M | −€11.0M | −€12.2M | −€10.1M | −€9.3M | −€8.1M | −€2.9M | −€7.7M | −€5.5M | −€5.4M |
| Income taxes | €25,413 | €1,000 | €991 | — | €18,000 | — | — | — | −€200,000 | €3,000 | €5,000 | €40,999 |
| Net income | −€8.9M | −€13.6M | −€8.8M | −€11.0M | −€12.2M | −€10.1M | −€9.3M | −€8.1M | −€2.7M | −€7.7M | −€5.5M | −€5.7M |
| EBITDA | −€8.2M | −€12.9M | −€8.4M | −€10.3M | −€11.5M | −€9.4M | −€5.8M | −€8.2M | −€2.2M | −€7.0M | −€291,000 | −€4.7M |
| Gross margin | 91.9% | 65.9% | 85.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −100.7% | −671.4% | −194.6% | −387.1% | −320.9% | −239.3% | −234.1% | −226.8% | −57.1% | −181.5% | −190.9% | −539.5% |
| Net margin | −99.6% | −658.3% | −190.3% | −377.6% | −319.1% | −223.0% | −216.0% | −211.0% | −42.7% | −172.1% | −167.0% | −416.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in PRQR's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PRQR financial results
In fiscal year 2025 (ended December 31, 2025), ProQR Therapeutics reported revenue of €15.3 million, down 19.2% from the year before. It had a net loss of €40.5 million, a net profit margin of −265.2%. Over five years revenue grew at an average rate of 71.5% a year. Figures are in euros, the currency of its financial statements.
See the PRQR stock overview for the latest quote and news, or the PRQR chart for price history and technical indicators.
PRQR income statement FAQ
What is ProQR Therapeutics's annual revenue?
ProQR Therapeutics reported total revenue of €15.3 million for fiscal year 2025, which ended on December 31, 2025. That was down 19.2% from €18.9 million the previous year.
Is ProQR Therapeutics profitable?
No. ProQR Therapeutics reported a net loss of €40.5 million in fiscal 2025, a net profit margin of −265.2%; its operating margin was −275.9%.
What is ProQR Therapeutics's gross margin?
ProQR Therapeutics's gross margin was 83.0% in fiscal 2025: for every $100 of revenue, ProQR Therapeutics kept $83 after the direct cost of its products and services.
How much does ProQR Therapeutics spend on research and development?
ProQR Therapeutics spent €40.7 million on research and development in fiscal 2025, 266.5% of revenue.
How fast is ProQR Therapeutics growing?
Revenue grew 71.5% a year on average over the last five fiscal years, from €1.0 million to €15.3 million.
When will ProQR Therapeutics report its next earnings?
ProQR Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does ProQR Therapeutics's fiscal year end?
ProQR Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.